文献速递牙体牙髓病儿童口腔

两种生物活性水门汀用于6-18岁恒牙不可逆性牙髓炎症状部分冠髓切断术的非劣效随机对照试验

Partial pulpotomy with two bioactive cements in permanent teeth of 6- to 18-year-old patients with signs and symptoms indicative of irreversible pulpitis: a noninferiority randomized controlled trial.
PubMed 文献 · Int Endod J · 2019-01-30

该非劣效随机对照试验纳入69颗6-18岁患者因不可逆性牙髓炎症状的恒第一磨牙,比较ProRoot MTA与Biodentine行部分冠髓切断术的疗效。平均随访32.2±17.9个月时,两组总体成功率90%(MTA 92%,Biodentine 87%,差异5%,95%CI -9%至19%,P=0.487),Biodentine不劣于MTA。Biodentine可察觉灰变发生率27%显著低于MTA的80%(P<0.001)。

要点

  • 部分冠髓切断术用MTA或Biodentine治疗6-18岁症状性不可逆牙髓炎恒牙成功率均约90%。
  • Biodentine成功率87%不劣于MTA的92%(差异5%,95%CI -9%至19%)。
  • Biodentine可察觉灰变27%显著低于MTA 80%(P<0.001)。

核心结论

  • 6-18岁患者有不可逆性牙髓炎症状的恒牙,使用ProRoot MTA或Biodentine行部分冠髓切断术均可成功治疗。
  • Biodentine的可察觉灰变发生率显著低于ProRoot MTA。

研究设计与样本

  • 非劣效随机对照试验,纳入69颗来自69例患者的恒第一磨牙,MTA组37颗、Biodentine组32颗。
  • 所有操作者在标准化方案下行部分冠髓切断术,使用复合树脂或不锈钢冠修复,每6个月复查。
  • 成功率比较用Fisher精确检验,灰变频率比较用卡方检验,显著性水平P<0.05。

主要发现

  • 平均随访32.2±17.9个月,67颗牙可评估(MTA 37颗,Biodentine 30颗),患者平均年龄10±2.1岁。
  • 两组基线变量(性别、年龄、牙位、根尖周状态、牙根发育阶段、最终修复及随访期)无差异。
  • 总体成功率90%,MTA组92%,Biodentine组87%,差异5%(95%CI -9%至19%,P=0.487),Biodentine非劣于MTA。
  • 可察觉灰变:MTA组80%,Biodentine组27%,差异有统计学意义(P<0.001)。

关键数值与推荐

  • 成功定义为评估牙必须同时达到临床和影像学成功。
  • 非劣效判定基于成功率差异的95%置信区间及预设显著性水平P<0.05。

临床怎么用

  • 对6-18岁有不可逆性牙髓炎症状的恒牙,可考虑部分冠髓切断术并使用ProRoot MTA或Biodentine。
  • 若美学上关注牙冠灰变,Biodentine可显著降低可察觉灰变风险。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To compare the outcome of partial pulpotomy using two cements, ProRoot MTA (Dentsply, Tulsa Dental Specialties, Tulsa, OK, USA) and Biodentine (Septodont, Saint-Maur-des-Fossés, France), in permanent teeth of 6- to 18-year-old patients with signs and symptoms indicative of irreversible pulpitis. Furthermore, the frequencies of perceptible grey discoloration caused by the cements were compared. METHODOLOGY: Sixty-nine permanent first molars with signs and symptoms indicative of irreversible pulpitis, from 69 patients, were included. All operators performed partial pulpotomy under a standardized protocol. Teeth were allocated, using a website-generated number of simple randomization, to partial pulpotomy with either ProRoot MTA (37 teeth) or Biodentine (32 teeth) and were restored with composite resin or stainless steel crowns. Patients were recalled every 6 months. To be categorized as having success, the evaluated tooth must have had both clinical and radiographic success. In addition, photographs of treated teeth were evaluated for frequency of perceptible grey discoloration. Success rates between the two cements were compared using the Fisher exact test. The frequencies of perceptible grey discoloration were compared using the chi-square test. The percentage difference was estimated by 95% confidence interval, and the level of significant difference was P < 0.05. RESULTS: At a mean follow-up of 32.2 ± 17.9 months, a total of 67 teeth, 37 with ProRoot MTA and 30 with Biodentine, were available for evaluation. The mean age of participants was 10 ± 2.1 years and, there were no differences in the baseline variables (gender, age, tooth type, periapical status, stage of root development, final restoration and follow-up period) between the groups. The overall success in both groups was 90%, with 92% for ProRoot MTA and 87% for Biodentine (difference, 5%; 95% confidence interval, -9% to 19%, P = 0.487), suggesting that Biodentine was noninferior to ProRoot MTA. Perceptible grey discoloration was observed in both groups, 80% for teeth treated with ProRoot MTA and 27% for teeth treated with Biodentine, with a significant difference between the materials (P < 0.001). CONCLUSIONS: Permanent teeth with signs and symptoms indicative of irreversible pulpitis in 6- to 18-year-old patients were successfully treated with partial pulpotomy using both cements. Biodentine exhibited significantly less frequency of discoloration than did ProRoot MTA.

来源:Int Endod J,查看原文。版权归原作者所有。

引用

  1. Uesrichai N, Nirunsittirat A, Chuveera P, et al. Partial pulpotomy with two bioactive cements in permanent teeth of 6- to 18-year-old patients with signs and symptoms indicative of irreversible pulpitis: a noninferiority randomized controlled trial. Int Endod J. 2019. PMID: 30638262. doi:10.1111/iej.13071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。